 Insect resistant plants |
| In accordance with one aspect of the present invention, there has been provided a method for ... |
|
| Hybrid toxin |
| What is claimed is: 1. An insecticidal Bacillus thuringiensis hybrid toxin fragment, comprising: a) ... |
|
| Antigenic proteins of Borrelia burgdorferi |
| It is an object of the present invention to provide a means for detecting mammals previously or ... |
|
| Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
| We claim: 1. An isolated DNA molecule consisting of a nucleotide sequence as shown in FIG. 3 for ACA... |
|
| Isolation and use of solid tumor stem cells |
| The invention claimed is: 1. A method for determining the capability of a test compound to inhibit ... |
|
| Hair analysis method |
| OF THE INVENTION In accordance with the present invention, a method is provided that permits the ... |
|
| Method for retarding or precluding Alzheimer's dementia |
| OF THE INVENTION The markers which are targeted according to the method of the invention are those ... |
|
| Streptococcus pneumoniae polynucleotides and sequences |
| OF ILLUSTRATIVE EMBODIMENTS The present invention is based on the sequencing of fragments of the S... |
|
| Protection against dental caries |
| I claim: 1. A process for producing an antigen preparation, for use in the reduction or prevention ... |
|
|
Methods of inhibiting GPR-9-6 function
| Details |
Inventors: Andrew, David P.; Zabel, Brain A.; Ponath, Paul D.;
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Primary Examiner: Nolan; Patrick J.
Assistant Examiner:
Attorney, Agent or Firm: Hamilton, Brook, Smith & Reynolds, P.C.
The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods. |
|
DETAILED DESCRIPTION The invention relates to an antibody (immunoglobulin) or functional fragment thereof (e.
g.
, an antigen-binding fragment) which binds to a mammalian GPR-9-6 (GPR-9-6 is also referred to as CC chemokine receptor 9 (CCR9)) or portion of the receptor.
In one embodiment, the antibody or antigen-binding fragment thereof binds to human GPR-9-6.
In another embodiment, the antibody or antigen-binding fragment thereof can inhibit the binding of a ligand to a mammalian GPR-9-6.
In a preferred embodiment, the antibody or antibody-binding fragment can bind to human GPR-9-6 and inhibit the binding of TECK to the receptor.
In particular embodiments, the antibody or antigen-binding fragment of the invention binds to an epitope which is the same as or is similar to the epitope recognized by mAb 3C3, mAb GPR96-1 or an antigen-binding fragment of either of the foregoing.
For example, the binding of the antibody or antigen-binding fragment of the invention to human GPR-9-6 can be inhibited by a peptide that consists of the amino acid sequence of SEQ ID NO:3.
In another embodiment, the binding of the antibody or antigen-binding fragment of the invention to human GPR-9-6 can be inhibited by mAb 3C3.
In a preferred embodiment, the antibody is mAb 3C3 or antigen-binding fragment thereof.
In a more preferred embodiment the antibody is mAb GPR-9-6 or antigen-binding fragment thereof.
The invention also relates to an isolated cell that produces an antibody or antigen-binding fragment of the present invention, including those which bind to mammalian GPR-9-6 and inhibit the binding of a ligand to the receptor.
In a particular embodiment, the isolated cell is murine hydridoma 3C3 (also referred to as murine hybridoma LS129-3C3-E3-1) deposited under ATCC Accession No.
11B-12653.
In another particular embodiment, the isolated hydridoma GPR96-1 (also referred to as murino hybridoma LS272 GPR96 1-5) deposited under ATCC Accession No.
PTA-1470.
The invention also relates to a method of detecting or identifying an agent (i
|
| Related patents |
|
|
Method for cloning of a rare, specifically mutated cell
The invention is a new and improved method for reliably detecting the presence of a rare cell having a desired nucleotide mutation that was introduced by a sequence-...
|
|
|
Vaccine against Gram-negative bacterial infections
OF THE PREFERRED EMBODIMENTS According to the present invention, a non-covalent, polyvalent complex between purified, detoxified LPS ("DLPS") derived from E. coli and ...
|
|
|
Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
The present invention relates to modified .beta.-chains of human hemoglobin having an oxygen binding affinity equal to or less than natural human hemoglobin. Preferably, ...
|
|
|
Inhibitor of stem cell proliferation and uses thereof
The present invention relates to polypeptides which are inhibitors of stem cell proliferation ("INPROL") and their use. The present invention includes an inhibitor of ...
|
|
|
Inhibitor of stem cell proliferation and uses thereof
The present invention relates to an inhibitor of stem cell proliferation (INPROL) characterized by the following properties: (a) Specific activity (IC.sub.50) less than ...
|
|
|
Method of inhibiting angiogenesis using secreted proteins
Isolated Proteins Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The ...
|
|
|
Balanced extraction system
The present invention is a device wherein matter to be extracted which contains various available components is kept in a state almost like a natural environment or, for ...
|
|
|
Compounds for the treatment of hepatoma
What is claimed is: 1. The method of treatment of a living subject affected by hepatoma which consists of administering to said subject by the oral route up to three ...
|
|
|
5ht2 agonists for controlling IOP and treating glaucoma
1. A method for lowering or controlling intraocular pressure or treating glaucoma which comprises administering a composition comprising a pharmaceutically effective ...
|
|
|
Insect resistant tomato and potato plants
We claim: 1. A chimeric gene capable of expressing in a plant cell comprising in sequence: (a) a promoter which functions in plants to cause the production of RNA; (b) a ...
|
|
|
Drugs 
